Bacterial infections in critically ill patients: review of studies published between 2006 and 2008;Infecciones bacterianas en el paciente crítico: revisión de los estudios publicados entre 2006 y 2008

Medicina Intensiva

Volumn 33, Issue 4, 2009, Pages 196-206

  Olaechea, Pedro M ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

Author keywords

Bacterial infections; Critically ill patients; Intensive medicine; Systematic review

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFTAZIDIME; CEFTRIAXONE; CHLORHEXIDINE; CIPROFLOXACIN; DALBAVANCIN; DORIPENEM; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MEROPENEM; MINOCYCLINE; MOXIFLOXACIN; ORITAVANCIN; PLACEBO; RIFAMPICIN; SULFADIAZINE; TELAVANCIN; VANCOMYCIN;

ARTIFICIAL VENTILATION; BACTERIAL INFECTION; CATHETER INFECTION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CRITICALLY ILL PATIENT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEALTH CARE SYSTEM; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; MONOTHERAPY; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; REVIEW; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-INFECTIVE AGENTS; BACTEREMIA; BACTERIAL INFECTIONS; CATHETER-RELATED INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; CRITICAL ILLNESS; HUMANS; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; PUBLISHING;

EID: 67649217319     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/S0210-5691(09)71216-1     Document Type: Review

References (88)

1. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 Suppl 2 (2007) S27-S72
2. Bodi M., Rodriguez A., Sole-Violan J., Gilavert M.C., Garnacho J., Blanquer J., et al. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis 41 (2005) 1709-1716
3. Shorr A.F., Bodi M., Rodriguez A., Sole-Violan J., Garnacho-Montero J., and Rello J. Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia. Chest 130 (2006) 93-100
4. Mortensen E.M., Restrepo M.I., Anzueto A., and Pugh J.A. Antibiotic therapy and 48-hour mortality for patients with pneumonia. Am J Med 119 (2006) 859-864
5. Calzada S.R., Tomas R.M., Romero M.J., Moragon E.M., Cataluna J.J., and Villanueva R.M. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission. Respir Med 101 (2007) 1909-1915
6. Dean N.C., Bateman K.A., Donnelly S.M., Silver M.P., Snow G.L., and Hale D. Improved clinical outcomes with utilization of a community-acquired pneumonia guideline. Chest 130 (2006) 794-799
7. Valencia M., Badia J.R., Cavalcanti M., Ferrer M., Agusti C., Angrill J., et al. Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest 132 (2007) 515-522
8. Marrie T.J., and Shariatzadeh M.R. Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore) 86 (2007) 103-111
9. Restrepo M.I., Mortensen E.M., Velez J.A., Frei C., and Anzueto A. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 133 (2008) 610-617
10. Shorr A.F., and Wunderink R.G. There is no «cap» on the importance of community-acquired pneumonia in the ICU. Chest 133 (2008) 590-592
11. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
12. Micek S.T., Heuring T.J., Hollands J.M., Shah R.A., and Kollef M.H. Optimizing antibiotic treatment for ventilator-associated pneumonia. Pharmacotherapy 26 (2006) 204-213
13. Carratala J., Mykietiuk A., Fernandez-Sabe N., Suarez C., Dorca J., Verdaguer R., et al. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med 167 (2007) 1393-1399
14. Alfageme I., Aspa J., Bello S., Blanquer J., Blanquer R., Borderias L., et al. Guías para el diagnóstico y tratamiento de la neumonía adquirida en la comunidad. Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Arch Bronconeumol 41 (2005) 272-289
15. Rodriguez A., Mendia A., Sirvent J.M., Barcenilla F., De la Torre-Prados M.V., Sole-Violan J., et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 35 (2007) 1493-1498
16. Robenshtok E., Shefet D., Gafter-Gvili A., Paul M., Vidal L., and Leibovici L. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev (2008) CD004418
17. Mortensen E.M., Restrepo M.I., Anzueto A., and Pugh J. The impact of empiric antimicrobial therapy with a beta-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care 10 (2005) R8
18. Lodise T.P., Kwa A., Cosler L., Gupta R., and Smith R.P. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 51 (2007) 3977-3982
19. Metersky M.L., Ma A., Houck P.M., and Bratzler D.W. Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. Chest 131 (2007) 466-473
20. Aspa J., Rajas O., Rodriguez C., Huertas M.C., Borderias L., Cabello F.J., et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 27 (2006) 1010-1019
21. Giamarellos-Bourboulis E.J., Pechere J.C., Routsi C., Plachouras D., Kollias S., Raftogiannis M., et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 46 (2008) 1157-1164
22. The Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 355 (2006) 2619-2630
23. Giantsou E., Liratzopoulos N., Efraimidou E., Panopoulou M., Alepopoulou E., Kartali-Ktenidou S., et al. De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med 33 (2007) 1533-1540
24. Kuti E.L., Patel A.A., and Coleman C.I. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care 23 (2008) 91-100
25. Gastmeier P., Sohr D., Geffers C., Behnke M., and Ruden H. Risk factors for death due to nosocomial infection in intensive care unit patients: findings from the Krankenhaus Infektions Surveillance System. Infect Control Hosp Epidemiol 28 (2007) 466-472
26. Medina J., Formento C., Pontet J., Curbelo A., Bazet C., Gerez J., et al. Prospective study of risk factors for ventilator-associated pneumonia caused by Acinetobacter species. J Crit Care 22 (2007) 18-26
27. Aloush V., Navon-Venezia S., Seigman-Igra Y., Cabili S., and Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 50 (2006) 43-48
28. Parker C.M., Kutsogiannis J., Muscedere J., Cook D., Dodek P., Day A.G., et al. Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. J Crit Care 23 (2008) 18-26
29. Rello J., Allegri C., Rodriguez A., Vidaur L., Sirgo G., Gomez F., et al. Risk factors for ventilator-associated pneumonia by Pseudomonas aeruginosa in presence of recent antibiotic exposure. Anesthesiology 105 (2006) 709-714
30. Georges B., Conil J.M., Dubouix A., Archambaud M., Bonnet E., Saivin S., et al. Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units. Crit Care Med 34 (2006) 1636-1641
31. Nseir S., Di Pompeo C., Jozefowicz E., Cavestri B., Brisson H., Nyunga M., et al. Relationship between tracheotomy and ventilator-associated pneumonia: a case control study. Eur Respir J 30 (2007) 314-320
32. Gasink L.B., Fishman N.O., Nachamkin I., Bilker W.B., and Lautenbach E. Risk factors for and impact of infection or colonization with aztreonam-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 28 (2007) 1175-1180
33. Fujimura S., Nakano Y., Sato T., Shirahata K., and Watanabe A. Relationship between the usage of carbapenem antibiotics and the incidence of imipenem-resistant Pseudomonas aeruginosa. J Infect Chemother 13 (2007) 147-150
34. Lodise T.P., Miller C.D., Graves J., Furuno J.P., McGregor J.C., Lomaestro B., et al. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. Antimicrob Agents Chemother 51 (2007) 417-422
35. Oztoprak N., Cevik M.A., Akinci E., Korkmaz M., Erbay A., Eren S.S., et al. Risk factors for ICU-acquired methicillin-resistant Staphylococcus aureus infections. Am J Infect Control 34 (2006) 1-5
36. Álvarez-Lerma F., Palomar M., Olaechea P., Otal J.J., Insausti J., and Cerdá E. Estudio Nacional de Vigilancia de Infección Nosocomial en Unidades de Cuidados Intensivos. Informe evolutivo de los años 2003-2005. Med Intensiva 31 (2007) 6-17
37. Aarts M.A., Hancock J.N., Heyland D., McLeod R.S., and Marshall J.C. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med 36 (2008) 108-117
38. Garnacho-Montero J., Sa-Borges M., Sole-Violan J., Barcenilla F., Escoresca-Ortega A., Ochoa M., et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 35 (2007) 1888-1895
39. Heyland D.K., Dodek P., Muscedere J., Day A., and Cook D. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 36 (2008) 737-744
40. Muscedere J., Dodek P., Keenan S., Fowler R., Cook D., and Heyland D. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: diagnosis and treatment. J Crit Care 23 (2008) 138-147
41. Pineda L.A., Saliba R.G., and El Solh A.A. Effect of oral decontamination with chlorhexidine on the incidence of nosocomial pneumonia: a meta-analysis. Crit Care 10 (2006) R35
42. Chlebicki M.P., and Safdar N. Topical chlorhexidine for prevention of ventilator-associated pneumonia: a meta-analysis. Crit Care Med 35 (2007) 595-602
43. Chan E.Y., Ruest A., Meade M.O., and Cook D.J. Oral decontamination for prevention of pneumonia in mechanically ventilated adults: systematic review and meta-analysis. BMJ 334 (2007) 889
44. Segers P., Speekenbrink R.G., Ubbink D.T., Van Ogtrop M.L., and De Mol B.A. Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine gluconate: a randomized controlled trial. JAMA 296 (2006) 2460-2466
45. Koeman M., Van der Ven A.J., Hak E., Joore H.C., Kaasjager K., De Smet A.G., et al. Oral decontamination with chlorhexidine reduces the incidence of ventilator-associated pneumonia. Am J RespirCrit Care Med 173 (2006) 1348-1355
46. Mori H., Hirasawa H., Oda S., Shiga H., Matsuda K., and Nakamura M. Oral care reduces incidence of ventilator-associated pneumonia in ICU populations. Intensive Care Med 32 (2006) 230-236
47. Taylor N., Van Saene H.K., Abella A., Silvestri L., Vucic M., and Peric M. Descontaminación digestiva selectiva. ¿Por qué no aplicamos la evidencia en la práctica clínica?. Med Intensiva 31 (2007) 136-145
48. Stoutenbeek C.P., Van Saene H.K., Little R.A., and Whitehead A. The effect of selective decontamination of the digestive tract on mortality in multiple trauma patients: a multicenter randomized controlled trial. Intensive Care Med 33 (2007) 261-270
49. Muscedere J., Dodek P., Keenan S., Fowler R., Cook D., and Heyland D. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: prevention. J Crit Care 23 (2008) 126-137
50. Heininger A., Meyer E., Schwab F., Marschal M., Unertl K., and Krueger W.A. Effects of long-term routine use of selective digestive decontamination on antimicrobial resistance. Intensive Care Med 32 (2006) 1569-1576
51. Al Naiemi N., Heddema E.R., Bart A., De Jonge E., Vandenbroucke-Grauls C.M., Savelkoul P.H., et al. Emergence of multidrug-resistant Gram-negative bacteria during selective decontamination of the digestive tract on an intensive care unit. J Antimicrob Chemother 58 (2006) 853-856
52. Niel-Weise B.S., Snoeren R.L., and Van den Broek P.J. Policies for endotracheal suctioning of patients receiving mechanical ventilation: a systematic review of randomized controlled trials. Infect Control Hosp Epidemiol 28 (2007) 531-536
53. Siempos I.I., Vardakas K.Z., and Falagas M.E. Closed tracheal suction systems for prevention of ventilator-associated pneumonia. Br J Anaesth 100 (2008) 299-306
54. Vonberg R.P., Eckmanns T., Welte T., and Gastmeier P. Impact of the suctioning system (open vs. closed) on the incidence of ventilation-associated pneumonia: Meta-analysis of randomized controlled trials. Intensive Care Med 32 (2006) 1329-1335
55. Jongerden I.P., Rovers M.M., Grypdonck M.H., and Bonten M.J. Open and closed endotracheal suction systems in mechanically ventilated intensive care patients: a meta-analysis. Crit Care Med 35 (2007) 260-270
56. Lorente L., Lecuona M., Jimenez A., Mora M.L., and Sierra A. Influence of an endotracheal tube with polyurethane cuff and subglottic secretion drainage on pneumonia. Am J Respir Crit Care Med 176 (2007) 1079-1083
57. Poelaert J., Depuydt P., De Wolf A., Van d V., Herck I., and Blot S. Polyurethane cuffed endotracheal tubes to prevent early postoperative pneumonia after cardiac surgery: a pilot study. J Thorac Cardiovasc Surg 135 (2008) 771-776
58. Rello J., Kollef M., Diaz E., Sandiumenge A., Del Castillo Y., Corbella X., et al. Reduced burden of bacterial airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study. Crit Care Med 34 (2006) 2766-2772
59. Gastmeier P., and Geffers C. Prevention of ventilator-associated pneumonia: analysis of studies published since 2004. J Hosp Infect 67 (2007) 1-8
60. Lorente L., Blot S., and Rello J. Evidence on measures for the prevention of ventilator-associated pneumonia. Eur Respir J 30 (2007) 1193-1207
61. Lorente L., Jimenez A., Santana M., Iribarren J.L., Jimenez J.J., Martin M.M., et al. Microorganisms responsible for intravascular catheter-related bloodstream infection according to the catheter site. Crit Care Med 35 (2007) 2424-2427
62. Bouza E., Alvarado N., Alcala L., Munoz P., Rabadan P.M., and Rodriguez-Creixems M. An instant procedure to demonstrate catheter-tip colonization may help clinicians. Diagn Microbiol Infect Dis 56 (2006) 255-260
63. Bouza E., Alvarado N., Alcala L., Perez M.J., Rincon C., and Munoz P. A randomized and prospective study of 3 procedures for the diagnosis of catheter-related bloodstream infection without catheter withdrawal. Clin Infect Dis 44 (2007) 820-826
64. Esteve F., Pujol M., Limon E., Saballs M., Argerich M.J., Verdaguer R., et al. Bloodstream infection related to catheter connections: a prospective trial of two connection systems. J Hosp Infect 67 (2007) 30-34
65. Ramritu P., Halton K., Cook D., Whitby M., and Graves N. Catheter-related bloodstream infections in intensive care units: a systematic review with meta-analysis. J Adv Nurs 62 (2008) 3-21
66. Kalfon P., De Vaumas C., Samba D., Boulet E., Lefrant J.Y., Eyraud D., et al. Comparison of silver-impregnated with standard multi-lumen central venous catheters in critically ill patients. Crit Care Med 35 (2007) 1032-1039
67. Osma S., Kahveci S.F., Kaya F.N., Akalin H., Ozakin C., Yilmaz E., et al. Efficacy of antiseptic-impregnated catheters on catheter colonization and catheter-related bloodstream infections in patients in an intensive care unit. J Hosp Infect 62 (2006) 156-162
68. Fraenkel D., Rickard C., Thomas P., Faoagali J., George N., and Ware R. A prospective, randomized trial of rifampicin-minocycline-coated and silver-platinum-carbon-impregnated central venous catheters. Crit Care Med 34 (2006) 668-675
69. Borschel D.M., Chenoweth C.E., Kaufman S.R., Hyde K.V., VanDerElzen K.A., Raghunathan T.E., et al. Are antiseptic-coated central venous catheters effective in a real-world setting?. Am J Infect Control 34 (2006) 388-393
70. Gastmeier P., and Geffers C. Prevention of catheter-related bloodstream infections: analysis of studies published between 2002 and 2005. J Hosp Infect 64 (2006) 326-335
71. Niel-Weise B.S., Stijnen T., and Van den Broek P.J. Anti-infective-treated central venous catheters: a systematic review of randomized controlled trials. Intensive Care Med 33 (2007) 2058-2068
72. Niel-Weise B.S., Stijnen T., and Van den Broek P.J. Anti-infective-treated central venous catheters for total parenteral nutrition or chemotherapy: a systematic review. J Hosp Infect 69 (2008) 114-123
73. Gilbert R.E., and Harden M. Effectiveness of impregnated central venous catheters for catheter related blood stream infection: a systematic review. Curr Opin Infect Dis 21 (2008) 235-245
74. Raad I., Hanna H., and Maki D. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect Dis 7 (2007) 645-657
75. Eggimann P. Prevention of intravascular catheter infection. Curr Opin Infect Dis 20 (2007) 360-369
76. Timsit J.F. Diagnosis and prevention of catheter-related infections. Curr Opin Crit Care 13 (2007) 563-571
77. Pronovost P., Needham D., Berenholtz S., Sinopoli D., Chu H., Cosgrove S., et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 355 (2006) 2725-2732
78. Silvestri L., Van Saene H.K., Milanese M., Gregori D., and Gullo A. Selective decontamination of the digestive tract reduces bacterial bloodstream infection and mortality in critically ill patients. Systematic review of randomized, controlled trials. J Hosp Infect 65 (2007) 187-203
79. Swoboda S., Ober M., Hainer C., Lichtenstern C., Seiler C., Wendt C., et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother 61 (2008) 729-733
80. Fowler Jr. V.G., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., Rupp M.E., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355 (2006) 653-665
81. Bassetti M., Righi E., Fasce R., Molinari M.P., Rosso R., Di Biagio A., et al. Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit. J Antimicrob Chemother 60 (2007) 433-435
82. Noel G.J., Bush K., Bagchi P., Ianus J., and Strauss R.S. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 46 (2008) 647-655
83. Stryjewski M.E., Chu V.H., O'Riordan W.D., Warren B.L., Dunbar L.M., Young D.M., et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 50 (2006) 862-867
84. Bhavnani S.M., Passarell J.A., Owen J.S., Loutit J.S., Porter S.B., and Ambrose P.G. Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50 (2006) 994-1000
85. Chen A.Y., Zervos M.J., and Vazquez J.A. Dalbavancin: a novel antimicrobial. Int J Clin Pract 61 (2007) 853-863
86. Jones R.N., Sader H.S., Stilwell M.G., and Fritsche T.R. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 58 (2007) 1-7
87. Torres A., Garau J., Arvis P., Carlet J., Choudhri S., Kureishi A., et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study -a randomized clinical trial. Clin Infect Dis 46 (2008) 1499-1509
88. Chastre J., Wunderink R., Prokocimer P., Lee M., Kaniga K., and Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 36 (2008) 1089-1096